Polyrizon (NASDAQ:PLRZ) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Polyrizon (NASDAQ:PLRZ) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Polyrizon in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Polyrizon presently has an average rating of “Sell”.

Polyrizon Stock Up 0.6%

NASDAQ PLRZ opened at $16.00 on Friday. The business has a 50 day simple moving average of $13.19 and a 200 day simple moving average of $10.90. Polyrizon has a one year low of $2.88 and a one year high of $2,235.00.

Polyrizon (NASDAQ:PLRZ) last released its earnings results on Saturday, February 14th. The company reported ($2.81) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Polyrizon stock. Jane Street Group LLC purchased a new position in Polyrizon Ltd. (NASDAQ:PLRZ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned approximately 1.35% of Polyrizon as of its most recent filing with the Securities and Exchange Commission (SEC).

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.